Literature DB >> 2334076

Cancer of the maxillary sinus treated with surgery and/or radiation therapy.

J H Isaacs1, S Mooney, W M Mendenhall, J T Parsons.   

Abstract

This is an analysis of 37 previously untreated patients with squamous cell carcinoma of the maxillary sinus treated with curative intent at the University of Florida from January 1966 through January 1984. All patients were followed for at least two years and 86 per cent (32/27) were followed for a minimum of five years. Patients were treated for cure with radiation therapy alone (25), surgery alone (1), or surgery and preoperative (6) or postoperative (5) radiation therapy. This study presents the results of treatment and the incidence of treatment-related complications in this group of patients.

Entities:  

Mesh:

Year:  1990        PMID: 2334076

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  4 in total

1.  Meta-analysis of outcome in anterior skull base resection for squamous cell and undifferentiated carcinoma.

Authors:  D E Eibling; I P Janecka; C H Snyderman; S P Cass
Journal:  Skull Base Surg       Date:  1993

2.  The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation.

Authors:  L Madison Michael; Jeffrey M Sorenson; Sandeep Samant; Jon H Robertson
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

Review 3.  Squamous cell carcinoma at maxillary sinus: clinicopathologic data in a single Brazilian institution with review of literature.

Authors:  Marcello Roter M Santos; João Paulo S Servato; Sérgio Vitorino Cardoso; Paulo Rogério de Faria; Ana Lúcia A Eisenberg; Fernando Luiz Dias; Adriano Mota Loyola
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

4.  Nasal cancer in leather workers: an occupational disease.

Authors:  G Battista; P Comba; D Orsi; K Norpoth; A Maier
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.